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ABSTRACT
Vaccination programs are designed to protect an animal from infection, however,
depending upon the age and health of the animal vaccination may not stimulate a
protective humoral response. It is possible that, as in the human and mouse models,
geriatric equines may be less responsive than their younger counterparts to current
vaccination protocols.

The purpose of this study was to identify an age related

diminution in the primary and secondary immune responses of geriatric horses in
response to vaccination. Two groups of horses were sampled. The first group consisted
of an open herd of 39 privately owned horses, varying in age from 2-27 years of age. The
second group consisted of a closed herd of 24 horses ranging in age from 7-over 30 years
of age. Each group was vaccinated twice intramuscularly with a commercial equine
influenza virus vaccine (Ft Dodge, A/Eq/KY/97). Additionally, one group was vaccinated
with keyhole limpet hemocyanin (KLH) in order to study a primary immune response to
a novel antigen. The other group was vaccinated with ovalbumin (OVA) for the same
purpose. Blood samples were obtained via jugular venipuncture prior to vaccination and
monthly thereafter for 5 months. All sera samples were analyzed for antigen-specific
antibodies using an ELISA assay. Our results show that all horses responded to primary
vaccination with either KLH or OVA, irrespective of age. In contrast, when vaccinated
with influenza the middle aged and older horses showed significant differences in the
their response between both the herds and the age groups.

Thus we were able to

demonstrate that age was not a factor in the generation of a primary immune response but
was a factor in the generation of a memory immune response. Future research should
focus on whether increased frequency of vaccination does in fact increase or maintain
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vaccine responses and whether antibody responses measured in vitro actually correlate
with protection in vivo.
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INTRODUCTION
Either following vaccination or primary infection the immune system utilizes a
complicated and elaborate strategy to prevent re-infection involving both cellular and
humoral responses.

Thus initial stimulation of the immune system leads to the

production of antigen-specific memory T & B-cells that will provide a rapid response to
future encounters with the same agent (1-3). Additionally, plasma cells are produced and
stimulated to secrete antibody both in the short and long term following vaccination or
infection (4, 5). This secretion of antibody will allow for a first line of defense in the
case of future contact with the pathogen.

Circulating antibody has the ability to

neutralize or opsonize invading organisms thereby presenting them to phagocytes or
CD8+ cells before they can infect the host (6).
Extensive research has been conducted regarding the structure and function of
antibodies in both the human and mouse model. The antibody molecule is composed of
two light chains and one heavy chain connected by a disulfide bridge at a hinge region
and together form a Y-shaped molecule. The antigen binding region (Fab) is composed
of two light chains and two heavy chains that together form a conserved domain and a
variable amino terminal domain. The constant region (Fc) contains heavy chains and is
highly conserved.

There are five major classes of Fc regions associated with

immunoglobulin isotypes that have been defined by anodal electrophoretic mobility:
alpha (α), delta (δ), epsilon (ε), gamma (γ), and mu (µ). It is from these distinct classes
that isotype names are derived: IgA, IgD, IgE, IgG, and IgM. The Fab and Fc regions
together confer bifunctional properties to the antibody molecule. The Fab region binds
antigen and the Fc region determines the particular isotype and function of the

molecule(7, 8). The hinge region also confers functionality to the molecule depending
upon its hinge-length and flexibility. (Figure 1) Increased flexibility may result in
reduced steric-hinderance by the Fab and also allow for greater avidity of the antibody
molecule (7, 9).
Antibody class and structure is highly conserved among different mammals, thus
it can be inferred that similar functions exist between the isotypes of differing species.

Light
Chain

Fab
Portion

Disulfide
Bridge

Fc Portion

Heavy
Chain

Figure 1: Structure of Immunoglobulin

IgM: IgM is the first isotype expressed during B-cell development and during a
primary immune response to infection. IgM is a polymeric antibody with five heavy
chain domains. Its unique pentamer shape gives it a high avidity for antigen and a greatly
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increased ability to fix complement. IgM makes up 5-10 % of the total serum Ig is also a
major antibody of the mucosal immune response, second only to IgA.
IgA:

IgA exists as either a dimer or a monomer and is predominantly found in

the mucosa, saliva, tears, and sweat. IgA makes up approximately 10-15% of the total
immunoglobulin component in the serum and is present mostly in its monomeric form.
Dimeric IgA is considered a first line of defense to any organisms infiltrating through the
mucosa, and dimeric IgA binds pathogens, thereby preventing their uptake across the
epithelium, and encouraging their removal via mucociliary transport. IgA also opsonizes
antigens that are later phagocytised by macrophages located on mucosal surfaces.
IgE: This isotype is found in the lowest concentrations of all the immunoglobulins in
sera, has the shortest half-life, is unable to activate complement, and cannot opsonize
antigens. This antibody is, however, the primary effector of Type I hypersensitivity
responses and is a potent initiator of the inflammatory response. After release by plasma
cells, IgE is bound by the Fcε receptor on basophils and mast cells. Once the crosslinking membrane bound IgE antibodies bind antigen, they will induce degranulation of
the host cell.
IgG: As the most prevalent immunoglobulin in plasma, this class makes up over
75% of the total Immunoglobulin in the serum. Four subclasses have been identified in
human and mouse models, IgG1, IgG2, IgG3, IgG4. In the horse, these subclasses are
divided up as follows; IgGa, IgGb, IgGc, IgG(T). Despite the different nomenclature
used for different species, it is believed that various subclasses share similar functions.
For instance, in the mouse, IgG1and IgG4 in the human are associated with immune
responses to parasites and allergens (6).
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The IgG subclasses also are capable of fixing complement, and do so to varying
degrees.

This variation in the ability of complement fixation may be a result of

differences in the hinge region of each subclass, thus resulting in possible sterichinderence properties (10-12).
Isotype production is indirectly governed by Th cells, which secrete cytokines that
regulate isotype switching in B-cells. In the mouse, production of IgG2a is a result of
expression of IL-2 and IFNγ by Th1 cells. IgG1, however, is produced in response to Th2
cell expression of IL-4, IL-5, and IL-10 (13). IgA and IgE are also products of a strong
Th2 response.

In the human IgG1 and IgG3 are produced in response to cytokine

expression by Th1 cells (14).
Until recently very little has been learned regarding the humoral response and the
antibody repertoire in horses. In 1939, the first equine isotypes, IgG and IgM were
described followed in 1940 by the identification of a ‘T-protein’(15). This ‘T-protein’
was originally considered to be a homologue of IgA, but structural and antigenic studies
conducted by Weir et al. (16, 17), and Widders et al. (17) show it to be a subclass of IgG
and was subsequently identified as IgG(T). IgGa, IgGb, and IgGc were identified as IgG
subclasses thru the use of electrophoretic anodal mobility (18). Nine equine Ig isotypes
have currently been described: IgA, IgM, IgGa, IgGb, IgGc, IgG(T), and IgE(19-25),
while recent work done by Overesch et al has isolated six immunoglobulin G heavy
chain(cγ) genes in the equine haploid genome (cγ1- cγ6) (26).
Of the equine isotypes, IgGb is found in significantly greater concentrations in the
serum (>60%) of adult ponies and horses, followed by IgG(T)and IgGa. IgGc and IgA are
found in low concentrations in sera (27). In contrast to serum samples, nasal washes
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contain predominantly IgA with low concentrations of IgGb and IgGa found. IgGc has
not yet been detected in nasal washes of the horse (16, 27).
The development of monoclonal antibodies (mAb) allows for advanced studies of
antibody isotypes. Work done by Sheoran et al (24) and Sugruia et al (25) has shown
success in the production of hybridomas secreting antibodies specific for six equine
isotypes; IgA, IgGa, IgGb, IgGc, IgG(T), and IgM. These MAbs are an invaluable tool in
determining Ig concentration in mucosal and serum fluids, determination of antibody
half-life, and antibody response to specific types of antigenic presentation to name a few.
Age effects on the immune response
Horses over 20 years of age constitute about 15% of the equine population and
many remain actively involved in equestrian sports and reproductive capacities as
stallions and brood mares (28). However, advancing age in horses, as with other species,
is eventually associated with a decline in body condition and muscle tone as well as an
increase in susceptibility to infections (29-31). This increased susceptibility to infectious
diseases is due to an overall decline in immune function that results from alterations of
many different elements of the immune system.

While these changes have been

extensively documented in humans and mouse models, little research has been done in
the equine system. Vaccination remains the most cost-effective measure for preventing
and reducing the severity of infectious diseases in the equine population (32). Little is
known, however, regarding the effectiveness of vaccinations in the geriatric equine
In order to elucidate the complex events that are involved in immunosenescence
we must first consider how the immune system responds to infection. All animals, upon
parturition, have a natural or innate immunity that acts as a limited but rapid response to
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infection that does not require prior exposure to the pathogen (33-35). These aspects of
the immune response include the chemotactic attraction of phagocytic and cytotoxic cells
to the site of the infection and the subsequent production of soluble mediators.
Macrophages and neutrophils are the key cells involved in the phagocytosis of invading
organisms. Macrophages are also the source of various chemokines that recruit other
phagocytic cells, including neutrophils, to the infected area. Chemokines also act on
local blood vessels causing vasodialation, increased vascular permeability, and the
eventual exudation of plasma and cells to the site of ongoing infections (34).

Other

soluble mediators involved in this phase of the innate immune response are mannosebinding protein, serum amyloid protein, and complement proteins that bind to prokaryotic
carbohydrate structures and facilitate their uptake by the phagocytic cells (36). Natural
killer (NK) cells are cytotoxic effector cells that play a central role in the innate immune
response to tumors and virus-infected cells (37). The non-specific cytotoxic activity of
NK cells can be further enhanced by the cytokines interleukin (IL)-2 and interferongamma (IFNγ). These so-called lymphokine activated killer (LAK) cells are capable of
lysing tumor cells resistant to NK-mediated lysis. NK cells are also the source of IFNγ
and as such can augment macrophage microbicidal and tumorcidal activity (37).
To date, most research has not shown a significant alteration in innate immune
function between young and old individuals, though some subtle alterations may be
present. Thus there is a general decline in function of the phagocytic capabilities of
human neutrophils (35). Likewise there is also a slight increase in the susceptibility of
human neutrophils to apoptosis with advanced age (38).

Whether these alterations

contribute to increased susceptibility to infection in the elderly remains unknown. By
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contrast, the phagocytic and bactericidal activities of pulmonary macrophages and
neutrophils from young and aged mice appear comparable (39).

Alterations in

macrophage cytokine production could also play a role in the increased susceptibility of
elderly individuals to endotoxins (40). This impairment of cytokine production could
have important impacts on the induction of specific immune responses, as discussed
below. Similarly, ageing is associated with a decrease in the cytolytic activity of NK
cells in circulation, though this appears to be offset by an increase in the total number of
these cells in the circulation (36, 37, 41, 42). This functional decline in NK activity may
be the result of decreased responsiveness to IFNγ and IL-2 (36, 41, 42).
A few studies have assessed the effect of ageing on innate immune responses of
horses. Overall LAK cell activity in old, Standardbred mares appears equivalent to that
seen in younger mares (43), though the possibility of there being fewer cells in
circulation was not assessed. In another study there was no differences in the circulating
numbers of monocytes or granulocytes between young and aged horses (44). Nor was
there an effect of ageing on the respiratory burst activity of equine neutrophils (44).
These results are thus in agreement with most other studies indicating that ageing has
little effect on the innate immune responses (45).
Acquired or adaptive immunity involves the induction of cellular and humoral
immune responses directed against a specific antigen.

Adaptive immunity is also

characterized by the development of cellular memory that provides a more rapid
secondary response upon re-exposure to the antigen. Acquired immunity involves two
major cell types: B-lymphocytes and T-lymphocytes.
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B cells are responsible for the production and secretion of antibodies. While each
individual B cell has its own unique antigen-specificity, the process of gene
rearrangement during B cell ontogeny leads to the development of B-cells with
specificity for 107 different antigens. The product of pluripotential hematopoietic stem
cells, the B-cell matures in the bone marrow and then migrates to secondary lymphoid
tissues. Upon exposure to its antigen, the B-cell can proliferate and differentiate into an
antibody secreting plasma cell, or it may become a memory B-cell. Activation of a
memory cell by re-exposure to a specific antigen leads to a rapid antibody response.
Ageing markedly reduces antibody production in both humans and mice (46).
Though the total number of B-cells in circulation does not appear to be reduced in aged
mice, there is a marked decrease in B-cell ontogeny and increased signs of apoptosis (46).
There also appears to be decreased migration of plasma cells to effector sites in old
animals (47). This latter effect could have significant impact on the development of local
immune responses at mucosal surfaces. Advanced age is also associated with an overall
shift to antibodies of lower affinity for their specific antigen (48). In young animals, the
maturation of the antibody response is associated with an increased affinity of antibodies
for their specific antigen. This increased affinity is the result of somatic mutations in the
variable region of the immunoglobulin genes. The reduced affinity seen in the elderly
can be attributed to the age-related reduction in germinal center reactions and
immunoglobulin hypermutation (49).
Lower affinity and reduced B-cell responsiveness to antigen could account for the
reduced efficacy of vaccinations in older individuals (50).

While current vaccine

formulations are highly efficacious in young, healthy recipients (51), their failure rate in
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the elderly may be as high as 50% (52).

Altered responses, particularly in terms of

immunoglobulin isotypic responses, are also seen in elderly recipients (50). Thus elderly
patients produce antibodies of a different isotype compared to younger vaccinates (50,
53, 54). Similar results have been obtained in rodent models (55).
Ageing in horses is likewise associated with reduced antibody responses to
vaccination (43, 56). In one study, the proportion of horses producing hemagglutinationinhibition (HI) antibodies following equine influenza virus vaccination decreased with
advancing age such that no HI antibody responses were seen in horses over 9 years of age
(56). When antibody responses were measured by ELISA, a more sensitive measure of
total antibody responsiveness, a significant decrease in influenza virus-specific antibody
levels was seen in horses greater than 20 years of age following vaccination, as compared
to a younger cohort (43). The mechanism of this decline is unknown but appears to be
secondary to alterations in T-cell function (43).
While alterations in B-cell ontogeny and function can contribute to decreased
humoral responses in the elderly, it is now believed that the dramatic effects of ageing on
immune competence are the results of deteriorations in T-cell function (57). T-cells are
produced primarily in the thymus as the result of the emigration of T-cell precursors from
the bone marrow to this organ. Thymic development involves both the generation and
the so-called “education” of T-cells to recognize specific antigen in the context of self
major histocompatability complex (MHC) antigens. Thymic selection gives rise to the
two major subsets of T-cells, CD4+ helper T-cells and the CD8+ cytotoxic T-cells. The
CD8+ T-cell recognizes its foreign antigen in association with MHC Class I antigens that
are present on the surface of all nucleated cells. These cytotoxic effector cells play a
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primary role in the immune response to viruses and tumors lysing their target cells via a
variety of mechanisms (58). The CD4+ T-cells recognize foreign antigens presented in
the context of MHC Class II antigens found on macrophages and other antigen presenting
cells. The CD4+ T-cell population can be further subdivided into T helper (Th) subsets
based on the pattern of cytokines they produce. Th1 cells produce IL-2 and IFNγ, and
Th2 cells produce IL-4, IL-5, and IL-13. The significance of this segregation of cytokine
production is that Th1 cytokines are associated with immune responses to intracellular
pathogens, whereas the Th2 response is directed against extracellular agents (59).
Therefore, immunity to viruses and intracellular parasites is mediated by Th1 cells,
whereas protection against intestinal helminths involves Th2 responses. Though initially
described in murine models, similar patterns of Th subsets have been described in other
species, including the horse (60).
One of the most consistent changes noted in immune competency with advancing
age is the decrease in the number of naive T-cells with a concomitant increase in T-cells
with an activated/memory phenotype (61). While it has long been established that with
age there is a significant involution of the thymus and a resulting decline in naïve T-cell
production (61-63), increased apoptosis and lower responsiveness of aged lymphoid cells
to activation and proliferation signals also contribute to this process (64).

Thus T

lymphocytes derived from elderly humans are more susceptible to activation-induced cell
death than T-cells from young individuals (65). While this increase in apoptosis could
be the result of increased FAS antigen (CD95) expression on the T-cell surface (66),
alterations in normal signaling pathways via other receptors might also contribute to this
effect (67-69). In addition to an increased susceptibility to apoptosis, T-cells from aged
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individuals also exhibit an impaired proliferative capacity (61).

This reduced

proliferative capacity is the result of the diminished production of IL-2 by aged T-cells
(61, 70). The reduction in IL-2 production is itself associated with the reduced activation
of various intracellular signaling pathways (68, 71-73), particularly those initiated by the
T-cell receptor/CD3 complex (74-76). The central role IL-2 plays in age-associated
alterations in T-cell function is evident in those studies where supplementation with this
cytokine could restore immune responsiveness both in vitro and in vivo (77, 78).
Ageing in horses is associated with similar changes in the thymus and the
circulating T-cell compartment (79, 80). When compared to their neonatal counterparts,
MHC II expression is increased on the T lymphocytes of adult horses (80). This is
consistent with a shift towards a larger memory T-cell population with age as seen in
other species. Ageing in equids is also associated with a decreased proliferative response
of their T-cells to in vitro stimulation with mitogens (43, 81).

Though there was no

difference in the overall expression of the IL-2 receptor on mitogen-stimulated T-cells
from young and aged ponies, supplementation of these cultures with recombinant IL-2
failed to restore the proliferative response of the older cells (81). These results indicate
that alterations in IL-2 production alone may not play a central role in age-associated
immune deviation in the horse.
While the decreased proliferative responses of T lymphocytes from elderly
humans and mice is correlated with decreased release of IL-2, the expression of other
cytokine genes and their receptors may also be affected (82). Indeed many of the
problems associated with an ageing immune response may be due to age-dependent
alterations in cytokine gene expression by CD4+ T-cells (82-84).
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While the pattern of

these changes is complex, ageing appears to be generally associated with a decline in Th1
cytokine expression and a concomitant increase in susceptibility to those infections best
controlled by this type of response (77, 85). This increased susceptibility to infection is
compounded by ageing-associated alterations in CD8+ T-cell function. As age increases,
there is a resultant decrease in the cytotoxic activity of virus-specific CD8+ cells in
humans (86). This decreased cytotoxicity is associated with a decline in perforin gene
expression (87). A similar decline in cytotoxic activity and IFNγ production is seen in
aged mice and is associated with increased susceptibility to viral infection (88).
The central thesis of this review has been a focus on the changes that occur in the
immune responses of older individuals.

While it is clear that current vaccination

strategies may have to be modified to address the unique needs of the older human (51)
and equine populations, an important point to consider is the effect of other health
conditions on the immune system. There is good evidence that healthy individuals of
advanced age can respond to vaccinations as well as younger individuals (89-91).
Variations in vaccine responses of the elderly may be most dependent upon individual
genetic variations (89), health status (92-94), and other external factors (95). Similar
considerations apply when evaluating the effect of ageing on the ability of horses to
respond to vaccination. The adverse effect of parasitism on vaccine responses in the
horse has been recently reported (96). While adult horses tend to have lower levels of
parasitism than younger animals, aged individuals may also have elevated levels despite
the active use of anthlminthics (97-99). The effect of various stressors on immune
responses in both humans (100, 101) and horses is also well recognized (102, 103).
Dietary and nutritional status are widely viewed as important factors affecting immune
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responsiveness of the aged population (104-107).

All of these factors must be

considered when vaccinating both aged and young horses.
In order to assess the effectiveness of vaccination on aged horses, we vaccinated
two populations of privately-owned, mixed aged horses to novel and recall antigens and
assessed their antibody response to these vaccines by ELISA.

This study required

dividing both herds into three age groups, young, middle, and old. The three age groups
were selected in an attempt to maintain a normal distribution of horses between both
populations. The age groups were divided as follows: Young, 1-10 years, middle, 11-19
years, and old, 20+.
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MATERIALS AND METHODS
Horses. A group of 36 horses maintained at the BREC Farr Park Horse Activity
Center (Baton Rouge, LA) that have been vaccinated annually for equine influenza using
commercially available inactivated virus products.

A second group of 24 horses

maintained at the Marydale Girl Scout Camp (Table 1) were not routinely vaccinated for
equine influenza virus prior to inclusion in this study. Each group was of mixed sex,
breed and age. The BREC horses were kept in stalls during the week and put out to
pasture on weekends. While stalled they were fed a pelleted ration and sweet feed
(Purina Stable Star, St Louis, MO). The Marydale horses were kept primarily on pasture
and brought in daily to be given a pelleted feed. The BREC herd was considered an
“open herd” as horses routinely entered and left the facility. The Marydale horses were a
closed population with no new additions during the course of this study (Table 1).
Table 1: BREC and Marydale horses
BREC
NAME
Roxanne
Molly
Ari
Zack
Debbie
Sweetpea
Prince
Maya
M&M
Chic
Leroy
Donna
Jack
Casey
Pooh
Patience
Skip
Blaze

AGE
2
4
5
5
6
6
7
9
9
10
10
10
10
11
11
11
11
13

NAME
Missy
Star
Beaux
Blue
Angel
Dolly
Daisy
Hannah
Trojan
Teddy
Rudy
Pal
Love
Zayid
Wiggins
Amigo
Doc

Marydale

AGE
13
14
14
16
16
16
17
17
19
19
20
20
23
24
25
26
27

NAME
Nevada
Molley
Babydoll
Sassy
Spider
Buckshot
Eagle
Penny
Apache
Ariel
Patches
Peggy
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AGE
7
8
11
11
12
13
13
14
15
16
16
16

NAME
Dallas
Pretty
Kneehigh
Little Rick
Puddin
Roman
Chester
Chief
Mickey
Scout
Taylor
Pj

AGE
17
17
18
19
19
19
20
20
21
22
22
30

Vaccination.

Both populations of horses were vaccinated with a deep

intramuscular injection on the right side of the neck into the serratus cervicis with 1 mL
of a commercially-available, formalin-inactivated equine influenza virus vaccine
(Fluvac+, Fort Dodge Laboratories Inc., Fort Dodge, IA) that contained the
A/Equine/Kentucky/91 strain of influenza virus.

The BREC horses also received,

immediately after the flu vaccination, a 1 mg dose of ovalbumin (OVA, Sigma, St Louis,
MO) in alum adjuvant (OVA, Sigma, St Louis, MO). Shortly after a 1 ml vaccination of
inactivated influenza virus, the Marydale horses were vaccinated intramuscularly with 1
mg of Keyhole Limpet Hemocyanin (KLH, Sigma, St. Louis, MO) also in an alum
adjuvant.
Serum collection. Blood was collected aseptically into vacutainer tubes (Becton
Dickinson & Co., Franklin, NJ) via jugular venipuncture one month before vaccination
and at monthly intervals post vaccination for seven months. The blood was clotted and
subsequently centrifuged for 10 minutes at 1000 rpm to separate the serum. The serum
was then withdrawn using a slow pipetting technique and stored in 2mL micro tubes
(Sarstedt, Numbrecht, Germany) at -20° C until later use.
Isotype quantitation. Antigen-specific equine antibody isotypes in the sera were
quantitated using a capture ELISA assay(108), as adapted for equine antibodies (109).
The first two rows of replicate 96-well plates were coated (50µL per well at 5µg of
antibody/mL) overnight with affinity purified polyclonal antibodies specific for an equine
immunoglobulin isotype (Bethyl Laboratories, Montgomery, TX).

Additionally, the

remaining wells were coated with specific antigen (50µL per well at 5µg of
antibody/mL). The plates were washed and subsequently blocked with 2% fish gelatin
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(Sigma, St. Louis, MO) in PBS. A standard curve was prepared on each plate by
applying an equine reference serum (Bethyl laboratories, Montgomery, TX) containing
known concentrations of antibody for each isotype to the wells coated with the affinity
purified antibody at a starting dilution of 1 µg/mL and serially diluted two-fold out to a
final concentration of .00781 µg/mL. Test serum samples, initially diluted 1/100 and
then two-fold to a final dilution of 1/400, were added in duplicate to the wells coated with
the specific antigen. The plates were then incubated for 60 minutes at 37° C. Following
incubation, the plates were washed and equine isotype-specific monoclonal antibody was
added at a dilution that produced an absorbance at the midpoint of the standard curve.
Equine isotype-specific murine monoclonal antibodies (mAbs) to IgA, IgGb (CVS 39),
IgGa (CVS 45), and anti-IgG(T) (CVS 38) were kindly provided by Dr. Paul Lunn
(Madison, WI). Each was used as a hybridoma generated supernate. Following a 60minute incubation, the plates were washed with an ELISA wash consisting of PBS, 25%
Tween-20, and deionized water. Subsequently, an HRP-conjugated goat-anti-mouse IgG
antibody (BD Biosciences, San Diego, CA) was added at a 1:2400 dilution. The plates
were again incubated for 60 minutes and washed with ELISA wash.

A TMB1-

component (3,3’,5,5’-tetramethylbenzidine) peroxidase-substrate solution (75µl per well)
(Kirkegaard & Perry Laboratories, Gaithersburg, MD) was added to each well. This
caused a color-change (blue) to occur that was allowed to develop for 5 minutes. Then
the reaction was stopped with a 1% HCL solution (Kirkegaard & Perry Laboratories,
Gaithersburg, MD).

The plates were read at 450nm using the MRX microplate reader

(Dynex Technologies, Chantilly, VA). The results generated by the reference curve
allowed sample results to be expressed in µg/mL.
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Cross-reactivity ELISA. Four plates were coated with IgA, IgGa, IgGb, and
IgG(T) polyclonal antibodies such that each isotype was applied across each plate in two
rows at a concentration of 5µg/ml. The plates were then stored overnight at 4° C. The
plates were then washed with ELISA wash and blocked with a 2% Fish gel and PBS
solution for 60 minutes at room temperature. Reference serum was added to each plate at
the concentration specific to each isotype: IgGa 2.2 mg/ml, IgGb 9.55 mg/ml, IgG(T)
10.6 mg/ml, IgA 1.15 mg/ml, IgM 1.5 mg/ml. After a 60 minute incubation at 37° C and
a subsequent ELISA wash an isotype-specific monoclonal antibody (anti-equine IgGa,
anti-equine IgGb, anti-equine IgA, anti-equine IgG(T)) was added at a 1:10 dilution to all
of the wells on a plate such that all four plates each received a different monoclonal per
plate. Following 60 minutes incubation the plates were washed and a goat-anti-mouse
IgG-HRP antibody was added at a 1:2400 dilution. The plates were again incubated for
60 minutes and then washed. Plates were developed with TMB1-component peroxidasesubstrate (75µl per well) and stopped, as previously described. The plates were read at
450nm with the MRX microplate reader [Dynex Technologies, Chantilly, VA].
Monoclonal antibody specificity assay. One plate was coated overnight with
5µg/ml of purified IgG(T) antibody. After washing and blocking the plate, mAb, of each
isotype, was added to the plate starting at a 1:10 dilution in a two-fold series. The plate
was then incubated for 60 minutes at 37° C and subsequently washed. HRP-conjugated
anti-mouse IgG antibody was added at a 1:2400 dilution to the wells and the plates
incubated and washed, as before. The plate was developed with TMB1-component
peroxidase-substrate solution and read at 450nm on the MRX microplate reader.

17

Monoclonal antibody assay. One plate was coated overnight at 5µg/ml with the
equine reference serum (Bethyl Laboratories). After washing and blocking the plate with
a 2% fish gel solution, isotype specific monoclonal antibody was added to the wells such
that each isotype was tested in duplicate. After a 60-minute incubation at 37° C, the plate
was washed and HRP-conjugated, anti-mouse IgG antibody was added at a 1:2400
dilution to the plate. After a final incubation and wash, the plate was developed with
TMB1-component peroxidase-substrate solution, and subsequently stopped with the 1%
HCl solution. Lastly, the plate was read at 450nm by the MRX microplate reader.
Reference serum radial immunodiffusion assay. The equine reference serum and
sera samples from three randomly selected horses were pippetted, undiluted, at 5µl per
well in a VET-RID radial immunodiffusion plate (Bethyl Laboratories) specific for
IgG(T). Following 18 hours incubation at room temperature, the precipitin rings were
measured to the nearest tenth of a millimeter using a light microscope equipped with an
ocular scale. A standard curve was established by plotting the ring diameter of each
standard onto a logarithmic scale.

The IgG(T) concentration of each sample was

determined by plotting its ring diameter on the standard curve.
Monoclonal antibody radial immunodiffusion assay.

The PermaRID Radial

Immunodiffusion Kit (QED Biosciences, San Diego) was used to quantify mAb
concentrations. Mouse IgG standards of 1000, 500, 250, & 62.4 µg/ml were pippetted
into wells on the gel at 20µl. Neat equine monoclonal antibody samples were pippetted
into wells at 20 µl per well in duplicate. The gel was then allowed to incubate at room
temperature for 48 hours. After incubation the gel was washed in phosphate buffered
solution (PBS) and subsequently blotted and rinsed with blotting paper and double-
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distilled water to remove excess indicator dye. Lastly, the gel was allowed to dry and the
precipitate was measured and plotted against a standard curve and the relative
concentrations were extrapolated from the corresponding numbers on the curve.
Polyclonal antibody specificity assay. Two plates was coated overnight with
5µg/ml of purifed IgG(T) antibody or purified IgA antibody. After washing and blocking
the plate, affinity-purified polyclonal goat anti-equine IgG(T) and affinity-purified
polyclonal sheep anti-equine IgA was added at 1 µg/ml and then incubated for 60
minutes at 37° C. Once the plate was washed, a biotinylated mouse anti-goat antibody
was added at a 1:50 dilution, titrated-out in a two-fold series, then incubated again for 60
minutes. After another wash, streptavidin was added at a 1:1000 dilution. Again, the
plate was incubated for 60 minutes and then washed, at which point the plate was
developed with TMB1-component peroxidase-substrate solution at 75µl per well and
subsequently the reaction was stopped and the plate read at 450nm by the MRX
microplate reader.
Competition ELISA. A plate was coated overnight with 5µg/ml of a goat antihorse IgG(T) polyclonal antibody per well in 50 ul volume. After blocking the plate, four
rows of wells receiv 1µg/ml of reference serum and the remaining four rows received
1µg/ml of purified equine IgG(T) (Bethyl laboratories). The plate was incubated for 60
minutes at 37° C and subsequently washed. Next a monoclonal IgG(T) antibody was
added to two of the

rows containing the reference serum and to two of the rows

containing the purified IgG(T).

An HRP-conjugated goat anti-equine IgG antibody

(Bethyl Laboratories, Montgomery, TX) was added to the remaining two rows in the
reference serum and the purified IgG(T) wells. After a 60 minute incubation and wash,

19

HRP-conjugated IgG antibody was added at a 1:2400 dilution to the wells that had
previously received the monoclonal antibody. The wells that had previously received the
HRP-goat anti-horse antibody, received an addition of 50µl per well of PBS in order to
prevent the wells from drying out. Lastly, after a 60-minute incubation and wash cycle
the plates were developed with TMB1-component peroxidase-substrate solution, stopped
as previously described, and read at 450nm with the MRX microplate reader (Fig. 2).

Epitope Competition Assay

Aff. Purified
PolyclonalIgG(T)
Serum IgG(T)
Purified IgG(T)
IgG(T) mAB
Mousea Horse
PolyclonalIgG(T)

Figure. 2: Epitope Competition Assay

Statistics. All data were analyzed using SAS (110). Comparisons of vaccine
response in all horses over time were evaluated by analyzing differences of the means of
each time period using a Tukeys Studentized test. In order to determine if there was a
difference in vaccine response in each age group per period (pre-vx. 1 mo, 3 mo, 5 mo, 6
mo, 7mo) a split plot design was used such that age group and individual horse within
age group were on the main plot, period and age group by period interaction on the
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subplot. The least squares means were then tested using ANOVA. Results were
determined significant at P ≤ 0.05.
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RESULTS
As expected three of the capture ELISA assays (IgA, IgGa, and IgGb) showed
excellent sensitivity and little cross reactivity for their respective isotypes (Figures 3-6).
However, the IgG(T) capture ELSIA failed to detect IgG(T) antibody in the reference
serum and appears to cross-react with IgA.
IgA Isotype X-reactivity
Coat 5 ug/mL

2
1.8
1.6
1.4

OD

1.2

IgA
IgGb

1

IgGa

0.8

IgG T

0.6
0.4
0.2
0
5

2.5

1.25

0.625 0.3125 0.1562 0.0781 0.039 0.0195 0.0097 0.0049
Ref Sera Diln

Figure 3: Crossreactivity of monoclonal antibodies with sheep anti-horse IgA polyclonal
antibody
To better characterize the specificity and apparent cross-reactivity of the antiIgG(T) and anti-IgA monoclonal antibodies, purified IgG(T) and IgA were used to coat
ELISA plates. Both of the monoclonal antibodies recognized their respective purified
antibody when bound to the ELISA plate directly (Table 2).

Neither monoclonal

antibody exhibited cross reactivity, nor did any of the other mAbs cross react with either
purified protein (Table 2).
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Figure 4: Crossreactivity of monoclonal antibodies with sheep anti-horse IgGa
polyclonal antibody.
IgGb Isotype X-Reactivity
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Figure 5: Crossreactivity of monoclonal antibodies with sheep anti-horse IgGb
polyclonal antibody
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Figure 6: Crossreactivity of monoclonal antibodies with sheep anti-horse IgG(T)
polyclonal antibody
Table 2: Specificity of IgA and IgG(T) monoclonal antibodies
Purified
IgG(T)

mAb

Diln 1:10
Anti-IgA OD 0.048
Anti-IgGb OD 0.059
Anti-IgGa OD 0.051
Anti-IgG(T) OD 0.894

1:20
0.052
0.048
0.046
0.709

1:40
0.048
0.049
0.047
0.640

1:80
0.047
0.052
0.071
0.395

1:160
0.050
0.050
0.050
0.316

NEG
0.057
0.054
0.057
0.056

Purified
IgA

mAb

1:20
1.155
0.044
0.046
0.045

1:40
1.062
0.045
0.050
0.049

1:80
1.087
0.051
0.054
0.047

1:160
1.061
0.054
0.047
0.044

NEG
0.058
0.053
0.056
0.054

Diln 1:10
Anti-IgA OD 1.192
Anti-IgGb OD 0.047
Anti-IgGa OD 0.046
Anti-IgG(T) OD 0.044

To rule out the unlikely possibility that the reference serum contained less IgG(T)
than specified by the manufacturer, radial immunodiffusion (RID) analysis of the serum
was performed. Results from the RID indicated that the reference serum concentration of
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IgG(T) was equivalent to that specified by the manufacturer and similar to that of three
randomly chosen serum samples (Table 3).

Table 3: RID Assay: IgG(T) concentration in reference sera and random sera .
Calc
Conc.
Samples (mg/dl)
Ref Sera 830
Ariel
830
Chief
1900
Dallas 1050
The amount of monoclonal antibody specific to each equine isotype in each
hybridoma supernate was determined using a mouse immunoglobulin specific radial
immunodiffusion assay. The anti- IgA, IgGa, and IgG(T) were all within the specified
range of the standard curve, except the anti-IgGb which was below detection levels
(Table 4).

Table 4: RID Assay: Anti-Equine antibody concentrations per supernate.
Linear
Trendline
Sample
anti Eq IgG(a)
anti IgG(b)
anti IgA
anti IgG(T)

Dil
1
1
1
1

Diameter
43
38
44
45

ug/ml
66.126
-14.684
82.288
98.45

As our results indicate, mAbs to equine IgG(T) and IgA showed excellent
specificity and sensitivity for their respective isotypes. We subsequently tested the antiIgG(T) and

anti-IgA polyclonal antibodies in a similar manner.
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Both polyclonal

antibodies were effective in the ability to recognize and bind to their respected purified
antigens when bound to an ELISA plate (Table 5). Additionally these two polyclonal
showed no cross-reactivity towards each other.

Table 5: Recognition of purified antigen by polyclonal anti-IgG(T) and IgA antibodies.
Polyclonal 1:50
IgG(T) OD 0.64
IgA
OD 0.28

1:100
0.512
0.239

1:200
0.566
0.152

1:400
0.554
0.151

NEG
0.042
0.042

In order to determine whether the IgG(T) monoclonal antibody was being blocked
by the polyclonal antibody, we tested whether a different antibody could detect the
captured IgG(T). Our results show that an HRP-conjugated polyclonal antibody is able to
bind the IgG(T) in the reference serum and purified IgG(T) captured in the ELISA but
that the monoclonal antibody to IgG(T) fails to bind either serum IgG(T) or the purified
antigen in the same assay (Table 6).

Table 6. Monoclonal anti-IgG(T) fails to detect the captured IgG(T) but a polyclonal
antibody does.
Detect
Ref Sera
mAb
Polyclonal
Purified IgG(T) mAb
Polyclonal

.5 ug/ml
-0.007
0.639
-0.002
0.636

.25 ug/ml
-0.014
0.55
-0.014
0.476

.0625
.125 ug/ml ug/ml
-0.013
-0.013
0.413
0.408
-0.015
-0.014
0.415
0.235

.0312
ug/ml
-0.013
0.211
-0.014
0.148

.0156
ug/ml
-0.014
0.13
-0.016
0.057

NEG
-0.009
0.013
-0.01
0.016

Both the BREC and Marydale horses were vaccinated with a commercially
available vaccine. Post-vaccination total influenza virus specific Ig levels in the BREC
herd were significantly elevated compared to pre-vaccination at 1, 3, and 5 months and
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returned to pre-vaccination levels by 6 months post (Figure 7). The post-vaccination
IgG(T) response to influenza vaccination was significantly different from pre-vaccination
levels at 1 and 3 months. The IgG(T) response to the flu vaccine began to fall off and
return to pre-vaccination by 5 months post. The influenza specific IgGb post-vaccination
levels were significantly higher only at 1 month post-vaccination. The return to prevaccination levels occurred rapidly after 1 month post-vaccination.

There was no

significant difference in the post-vaccination IgA antibody levels, however, despite a lack
of statistical significance there was a general increase in flu specific IgA levels
accompanied by a quick return to pre-vaccination levels. As noted above, in each
analysis, the duration of the vaccine response was relatively short-lived and returned to
near or below pre-vaccination levels within 3-5 months post-vaccination in the BREC
herd.
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Figure 7: BREC total Ig and isotypic antibody responses to Flu vaccine. Time periods
with letters in common are not significantly different by Tukeys studentized range (HSD)
Test (P ≤ 0.05).
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The Marydale herd established a similar pattern in the overall response to the flu
vaccine with the total Ig post-vaccination levels being significantly different from prevaccination values at all time points (Figure 7). The sub-isotype IgGb to the flu vaccine
was significantly higher than pre-vaccination at all post-vaccination time points. The
intensity of the IgGb response began to decrease after 1 month. There was no significant
difference in the influenza virus specific IgG(T) or IgA isotypes post-vaccination.
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Figure 8: Marydale total Ig and isotypic antibody responses to Flu vaccine. Time
periods with letters in common are not significantly different by Tukeys studentized
range (HSD) Test (P ≤ 0.05).
To assess the effect of ageing on the primary immune response to vaccination
both herds were vaccinated with of a novel antigen vaccine in an alum adjuvant. The
BREC herd received 1 mg of OVA in an alum adjuvant. The anti-OVA total Ig response
established classical signs of a primary immune response to vaccination with low prevaccination levels and a significant increase at all time points post-vaccination (Figure 9).
The duration of this response lasted 6 months. Similarly, the anti-OVA IgG(T) response
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reflected a classical primary immune response at all time points post-vaccination, though
antibody levels began to decline after 3 months. The OVA-specific IgGb levels were
even less long-lived than IgG(T) with significant differences from pre-vaccination levels
seen only at 1 month and 3 months post-vx. The IgA response increased significantly at
3 and 5 months with a return to pre-vaccination levels by 6 months.
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Figure 9: Total Ig and isotypic antibody responses to OVA vaccine. Time periods with
letters in common are not significantly different by Tukeys studentized range (HSD) Test
(P ≤ 0.05).
Similarly, the Marydale horses were given 1 mg of an experimental KLH vaccine
in an alum adjuvant. The total Ig response to KLH was quite vigorous with 1 month
post-vaccination EU levels exceeding that of either Flu or OVA antibody levels (Figure
10).

Likewise, the antibody levels at all other time points were significantly different

from pre-vaccination for the 7 months of the experiment. The KLH-specific IgG(T) was
significantly increased at 1 month and 3 months post-vaccination with the greatest
difference being at 3 months, after which, the anti-KLH IgG(T) levels rapidly returned to
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pre-vaccination levels. Anti-KLH IgGb increased significantly from pre-vx levels at 1
and 3 months. As with the other isotypes, the duration of the IgGb response was limited
to 3 months. The IgA response to KLH exhibited a significant increase at 1 month and 3
months post-vaccination.
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Figure 10: Total Ig and isotypic antibody responses to KLH vaccine. Time periods with
letters in common are not significantly different by Tukeys studentized range (HSD) Test
(P ≤ 0.05).
Within the BREC herd, old horses showed no significant difference in their total
Ig response to influenza vaccine at any time post-vaccination, while young and middleaged horses showed significant vaccine-induced increase in their post-vaccination
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antibody levels (Figure 11). Both middle-aged and old horses showed significantly
higher pre-vaccination antibody levels than their younger counterparts. Additionally,
middle-aged horse total Ig anti-influenza antibodies were significantly elevated at 5
months compared to young horses. All age groups showed significant increases in their
influenza specific IgG(T) levels and there was no significant difference between the age
groups and specific time periods. At 1 month post-vaccination, all age groups had
significant increases in their IgGb levels, which were followed by a rapid return to prevaccination titers. While young and old horses maintained similar levels of antibody at
all times middle aged horses had much higher levels of IgGb. Post-vaccination influenza
virus specific IgA levels were not significantly different from pre-vx levels in either
middle-aged or old horses. Young horses, however, did show a significant increase in
post-vaccination influenza virus specific antibody levels which lasted for 5 months postvx. Both middle aged and old horses did have higher levels of influenza-virus specific
IgA antibody when compared to the younger horses and were not significantly different
from each other. Old horses were also significantly different from young horses at 1
month post-vx while the middle aged horses were not.
The Marydale herd did not respond as well to influenza vaccination as the BREC
herd (Figure 12). The total Ig response showed significant differences mainly within the
middle age group. There was a significant increase in anti-influenza antibody in the
young group at 6 months and at 7 months in the old age group, but overall were generally
nonresponsive to vaccination.

Concomitant with this lack of responsiveness is the fact

that none of the Marydale horses showed any IgG(T) response to the influenza vaccine at
any time period, nor were there any differences between age group.
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IgGb-specific

response to the vaccine in middle-aged horses was seen at 1, 3, and 5 months postvaccination while old horses similarly showed significant increases at 1 and 3 months
post-vaccination, as such, the middle and old aged horses demonstrated significant
differences in influenza virus-specific IgGb antibody from there younger counterparts at
all time points. Young horses did not exhibit any IgGb-specific response to vaccination.
IgA levels remained relatively unchanged in the young horses. Middle-aged horses
showed a significant increase from pre-vaccination levels at all time points. In the old
age group, IgA levels actually declined following vaccination with a significant
difference from pre-vaccination antibody levels seen at 3 months post-vaccination. No
significant differences between the age groups were detected at any time point.
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Figure 11: BREC herd antibody response to Flu-vx within age group and between age
group by period interaction. Letters denote significant differences from pre-vx levels
within age group over time. Asterisk denotes significant differences from the young age
group of antibody levels at a specific time point. Test conducted by least squares means
analysis (P ≤ 0.05).
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Figure 12: Marydale herd antibody response to Flu-vx within age group and between age
group by period interaction. Letters denote significant differences from pre-vx levels
within age group over time. Asterisk denotes significant differences from the young age
group of antibody levels at a specific time point. Test conducted by least squares means
analysis (P ≤ 0.05).
In order to compare the difference in the primary antibody response to vaccination
in the aged horse from younger horses the BREC horses were each vaccinated with 1 mg
of an experimental OVA vaccine in an alum adjuvant. All age groups in the BREC herd
exhibited robust total Ig responses to OVA (Figure 13). The OVA-specific total Ig
responses of the middle aged and old horses were significantly higher than the younger
horses at 1 month and 3 months post-vaccination. Additionally, old horses also showed
significantly higher levels at 6 months when compared to young horses. All three agegroups exhibited a long duration of elevated antibody levels which continued over the
course of the 7 month experiment. As with the total Ig, the post-vaccination mean OVAspecific IgG(T) levels were significantly higher in all age groups when compared to their
respective pre-vaccination levels. No significant differences were observed between age
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groups at any time period. The OVA-specific IgG(T) response was long-lived, remaining
elevated over the 7 month course. All age groups did show an IgGb response to OVA
with significant increases seen at only 1 month post-vx. The greatest variability among
the age groups in BREC was with the IgA levels. The middle-aged horses had much
higher mean OVA-specific IgA levels pre-vaccination than the young and old horses. All
three groups did demonstrate significant increases in OVA-specific IgA antibody
following vaccination. The duration of the response in all three groups was 3 months
before returning to pre-vaccination levels. The middle-aged horses IgA response was
greater than that of younger horses at all time points. The old horses showed a significant
difference from the young horses at 1 month post-vx.
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Figure 13: BREC herd antibody response to experimental OVA-vx within age group and
between age group by period interaction. Letters denote significant differences from prevx levels within age group over time. Asterisk denotes significant differences from the
young age group of antibody levels at a specific time point. Test conducted by least
squares means analysis (P ≤ 0.05).
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To assess the primary immune response of the Marydale herd, horses were
vaccinated with 1 mg of an experimental KLH vaccine. Each age group responded to
vaccination demonstrating significant increases in the anti-KLH total Ig, and remaining
elevated for the 7 month study, however the middle-aged horses had significantly lower
levels of KLH-specific total Ig than either the young or old horses (Figure 14). The
IgG(T) response was very similar between the age groups. Each of the three age groups
demonstrated a significant increase in mean anti-KLH specific IgGb antibody at 1 and 3
months post-vaccination, and, there were no observed differences between the age
groups. Old horses additionally exhibited a greater anti-KLH specific IgGb response
when compared to the young and middle-aged horses, and maintained elevated IgGb
levels for 5 months before returning to pre-vaccination levels. The IgA response to KLH
vaccination was minimal with only the middle-aged horses exhibiting a significant
increase of anti-KLH IgA antibody at 1 month post-vaccination, however the middleaged and old horses maintained elevated levels of IgA for a longer duration with
significant differences from young horses at 7 months post-vx.

35

Total Ig KLH
1000000

b b
b b
a

EU 100000 a

* *
b b
*
a

10000

IgG(T) KLH
*
bb *
b
**
*
bb b

1000
bb
EU

a

b

100

b

b
aa

a

b
a

a

a

a a

a

a aa

10

1000
Yng Mean

Mid Mean

Old Mean

Yng Mean

Mid Mean

IgGb KLH
10000

EU 100

b

b

b

100000
b

b
EU
a

aa a

Yng Mean

a

a

aa a

Mid Mean

b

a
10000
a a
a

a

10
a

Old Mean

IgA KLH
b

b

1000

1

b
b

a

a

a
a a *
a

*

b

1000

Old Mean

Yng Mean

Mid Mean

Old Mean

IgGa KLH
100000

*

bb

b
bb b

b

10000

b
b

Log EU
1000

EU

aa a

100
a aa a

10
1

aa

aa aa
Yng Mean

a

a aa a
Mid Mean

a

aa
Old Mean

Figure 14: Marydale herd antibody response to experimental KLH-vx within age group
and between age group by period interaction. Letters denote significant differences from
pre-vx levels within age group over time. Asterisk denotes significant differences from
the young age group of antibody levels at a specific time point. Test conducted by least
squares means analysis (P ≤ 0.05).
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DISCUSSION
Immunoglobulin isotype expression plays a central role in determining the
ultimate functionality of the humoral immune response.

This is particularly true

regarding the use vaccination as a means of achieving protection against infectious
agents. Failure to induce the proper isotypic response may reduce the effectiveness of a
vaccine even if it contains the protective antigens. The functionality and molecular
regulation of isotype expression is well described for humans and mice, however, less is
known regarding this response in the horse.

There are isotypic-specific reagents

available for studying equine isotypes and sub-isotypes and a recent paper by Breathnach
et al (109), described a capture ELISA procedure using these reagents to quantitate
equine isotype and sub-isotype expression in an equine herpes virus model. Here we
have examined the issue of cross-reactivity and specificity of these reagents using a
similar procedure. While our results indicate that this method does discriminate between
the equine immunoglobulin isotypes and sub-isotypes with a fair degree of sensitivity, the
notable exception is an apparent cross-reactivity between IgA and IgG(T).

Somewhat

surprisingly, we also discovered that in some horses the IgG(T) capture ELISA failed to
work, presumably as a result of steric-hinderance.
Capture ELISAs are widely used to quantitate both specific antigen and
antibodies (111). While a number of protocols for capture ELISAs have been described,
the basic assay consists of an initial capture step typically involving a polyclonal antisera
followed by subsequent detection using a monoclonal antibody.

Variations include

different combinations of monoclonal or polyclonal antibodies for the capture or
detection phase. The specificity of the assay is determined by the affinity and the avidity
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of the two antibodies. While capture ELISAs composed of two monoclonal antibodies
have greater specificity for their respective antigen, they may be relatively insensitive due
to low affinity or avidity for the target antigen (111). Polyclonal antisera are often
preferred for the capture phase of the assay due to the greater affinity and avidity
associated with a population of antibodies, however, there is also a greater likelihood of
non-specific cross-reactivity occurring when polyclonal antibodies are used (111).
Cross-reactivity is defined as the ability of antibody to bind to ligands other than the
specific antigen. In the case of the equine IgG isotype specific reagents investigated
during this study, only low levels of cross-reactivity were detected for most of the
isotypes. The one exception to this was the apparent recognition of polyconally-captured
IgA in the reference sera by the anti-IgG(T) monoclonal antibody. Neither reagent
showed cross-reactivity against purified IgA or IgG(T).

IgG(T) was originally

considered to be a homologue of IgA, however structural and antigenic studies suggested
it was more likely a subclass of IgG (16, 17). While there have been previous reports of
a lack of cross-reactivity of the monoclonal anti-IgG(T) antibody for IgA (24, 112), these
were performed using IEP and SDS-PAGE analysis and not capture ELISAs as in the
current study. As the anti-IgG(T) monoclonal failed to recognize purified IgA, it is
possible that the crossreactivity with the reference serum was the result of a unique crossreactive epitope.

Though IgG(T) is the predominant isotype present in the equine

reference sera, we failed to initially detect it using the capture ELISA. Our RID results
confirmed that there were sufficient amounts of this isotype in the reference sera to be
detected using the capture ELISA. Both reagents were independently shown to detect the
IgG(T) in the reference sera as well as purified IgG(T). Nevertheless, they failed to work

38

together in the capture ELISA when the reference sera was used. They did work together
when sera from other horses were used in place of the reference sera (data not shown).
Together these results indicate that steric-hinderance or epitope competition between
polyclonal antibody, sera, and the monoclonal antibody prevented their use in a capture
ELISA. Our ability to detect the IgG(T) from some horses, but never the reference sera is
best explained by there being allotypic differences in IgG(T) between the horses. Possible
causes of binding interference may include: (1) the polyclonal and the mAb may bind to
the same epitope with either similar or different affinities, thus the polyclonal being
bound first blocks the mAb from binding. (2) The two reagents may bind separate
epitopes that overlap. The polyclonal being bound first would block part of the mAbs
epitope, thereby blocking it from binding. (3) Both reagents bind separate epitopes, but
the binding of the polyclonal to its epitope may cause a conformational change at a
distant site, thereby indirectly inhibiting the mAb from binding to its now
conformationally changed epitope (24). Since higher concentrations of IgG(T) mAb were
required to provide equivalent detection as the other monoclonals, it appears that the
IgG(T) mAb also has a relatively low affinity for its target. This would also be consistent
with the notion that the antibody is detecting an epitope with a high degree of allotypic
variation.
The goal of this study was to characterize both the memory and primary immune
response to vaccination in geriatric horses. There are numerous reports in the literature
describing age-related changes in immune function, particularly the immune response to
vaccination. Studies of age-related antibody responses in both the human and mouse
model have rendered conflicting results. In one study an increase in the serum IgG
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concentration with age was reported (113), while another study reported no change (114).
McFarlane et al have shown that advanced age in horses results in a decrease in
peripheral lymphocytes, T-cells, and B-cells which may contribute to an age-related
diminution in immunocompetency (115). Recent research in their lab has shown no
significant differences between young and old horses regarding serum concentrations of
IgM, IgG, and IgG(T) (116). Still very little research has been done regarding the effect
of ageing on antibody responses to vaccination in horses. Here we describe the results of
a vaccination study of two populations of horses with varying ages of 2-27 years. By
vaccinating with an equine influenza vaccine we are able to describe the memory
antibody response and the novel or primary response was defined by vaccination with
OVA or KLH.
Our initial analysis was of the memory antibody response, irrespective of age, to
vaccination in both populations (Figures 6, 7). Both herds elicited a robust antibody
response to equine influenza virus vaccination. Additionally, vaccination produced a
strong influenza specific IgGb antibody response in both herds, however the EU levels
for IgGb in the BREC herd were much higher indicating a more vigorous IgGb response
compared to the Marydale horses.

The only notable difference in specific isotype

responses between the two herds was that the BREC herd showed a flu specific IgG(T)
response to vaccination while the Marydale herd did not. The BREC herd is an open
population and is more frequently exposed to infection and subsequently vaccinated more
often, which may account for the high levels of anti-influenza IgG(T). These results are
in concurrence with research done by Nelson et al. (117). They observed a strong IgG(T)
response following vaccination with a killed Equine influenza virus. Additionally, their
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results indicated strong antibody responses by IgA, IgGa, and IgGb in the serum and
nasal mucosa of the naturally infected ponies but not in the vaccinated ponies. Neither
herd exhibited any type of IgA or IgGa specific response to influenza vaccination. This
is not unexpected since the vaccination was administered intramuscularly and may not
have induced an IgA response. Both populations exhibited similarities in the response to
influenza vaccination and in the duration of the antibody response.
Within age groups, only middle-aged horses demonstrated a flu specific total Ig
response to influenza vaccination in either herd (figures 10 and 11). The total Ig response
observed in the BREC herd is likely a result of a longer history of influenza vaccination
or exposure to natural infection compared to the Marydale horses. The middle-aged and
old BREC horses also had a significantly higher pre-vaccination total antibody levels
than the young horses which may possibly be the result of priming due to past exposures
to virus. An anti-influenza IgG(T) response was observed within each age group of the
BREC herd, while none was seen in any of the Marydale age groups. Again, this may be
explained by the more frequent vaccination of the BREC horses than the Marydale
horses. No significant differences were detected between any age group to anti-influenza
IgG(T) in either herd. All age groups from both herds manifested an anti-influenza IgGb
response, except for the young Marydale horses. The fact that only two horses comprised
this cohort may have skewed the analysis and may not be an accurate estimation of
antibody response in the younger horses.

At all time points, middle-aged and old

Marydale horses exhibited significantly higher anti-influenza IgGb antibody levels than
did the young age group. Within the BREC herd, only middle-aged horses exhibited a
significant increase over young horses in their anti-influenza IgGb levels. The old BREC
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horses exhibited a very limited IgGb response to vaccination, that was very similar to the
response seen in the younger cohort (Figure 10). An anti-IgA antibody response was
detected in the middle-aged Marydale horses and in the young BREC horses. It is
possible that the middle-aged Marydale horses had a recent natural exposure to virus,
however, we cannot explain why neither the young and old age groups failed to respond.
There were significant differences in pre-vaccination IgA antibody levels of middle-aged
and old horses from their younger counterparts in the BREC herd (Figure 10). The older
horses had much higher preexisting anti-influenza IgA titers. The overall lack of an IgA
response to the vaccine may be a result of the method of vaccination. IgA secreting
plasma cells predominate near mucosal surfaces so it would seem unlikely that
intramuscular vaccination would elicit much of an IgA response.
The two populations of horses were also vaccinated with a novel antigen. The
BREC horses were vaccinated with 1 mg of OVA in alum adjuvant and the Marydale
horses with 1 mg of KLH in alum adjuvant. Both herds demonstrated classical primary
immune responses among all isotypes measured (Figure 9).

This response was

characterized by a low pre-vaccination titer followed by an increase in antigen specific
antibody response of a short duration. Interestingly, the antibody response to KLH in the
Marydale horses was much higher than that of OVA antibody response in the BREC
herd. The Marydale horses demonstrated a strong IgGa response to KLH vaccination as
well (Figure 9) which was not detected in the OVA vaccinated horses (Data not shown).
The IgGa response to KLH in the Marydale herd was significantly increased in all three
age groups with no significant differences detected between them, but the old horses
maintained elevated anti-KLH antibody for a longer time than the young or middle-aged
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horses. It is possible that the KLH vaccine posses certain properties which induces an
IgGa response to a primary infection in the horse.
The total Ig response to KLH was significantly increased in each age group, but
the middle age group elicited significantly decreased antibody levels in comparison to
both younger and older horses. All three groups maintained elevated anti-KLH total Ig
for the course of the study. Although the Marydale horses demonstrated an IgG(T)
response to KLH, it was short-lived and no differences were observed between age
group. The same trend was observed in the anti-KLH IgGb response, however the
response in the old horses was of a longer duration. No significant differences were
observed in the IgA response to KLH.
All age groups in the BREC herd produced strong and long lasting anti-OVA total
Ig responses. In contrast to the Marydale herd, the BREC horses had a strong anti-OVA
IgG(T) response with a long duration. This suggests that the OVA response may be more
of a memory response since IgG(T) has been reported to be a strong element of the
secondary immune response (117). Ovalbumin is a constituent of many vaccines, and as
such may have primed the BREC horses, which may have yielded data that reflects more
of a memory than a naïve immune response.
No age related differences were observed with the anti-OVA IgG(T) response.
The anti-OVA IgGb response was similar to the Marydale IgGb response to KLH, with a
significant increase post-vaccination followed by a rapid return to pre-vaccination levels
by 3-5 months.

Middle-aged and old horses had significantly higher anti-OVA IgGb

levels than the younger horses, which may be a result of being primed more often. IgA
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responded to OVA vaccination strongly with significantly higher levels in the middleaged cohort than in any other group.
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CONCLUSIONS
There were a number of limitations that may have impacted our results; both
populations were privately maintained, no medical/ vaccination histories were recorded,
and we were unable to obtain an adequate number of young horses in the Marydale herd.
These limitations may have led to antigenic stimulation by introduction of new horses in
the BREC herd, without a medical/vaccination record we were unable to confirm any
preexisting conditions that may have had an impact on our results, and with only two
young horses in Marydale to use we may not have obtained accurate data regarding
primary exposure from that group. Nonetheless, our results suggest that the response to
primary infection is not age-dependent, but the response to secondary infection is agedependent.

Differences between open and closed herds have also been observed.

Populations with frequent antigenic stimulation produce stonger antibody resposnes to
secondary vaccination. We were unable to establish a true correlation between open and
closed herds due to the fact that the OVA response may not be a true primary response.
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RECOMMENDATIONS
Though vaccine manufacturers make no specific recommendations regarding the
vaccination of older horses and ponies, the similarities in age-induced immunological
changes between humans and equines suggests that similar vaccination recommendations
should be followed. The need for vaccination of the older horse will depend, of course,
upon the relative risk of exposure for the individual horse. Particular care should be
taken when using attenuated vaccine products as these live agents may pose a unique risk
to the older individual. Immunization with inactivated agent vaccines are thus likely to
be safer. Although inactivated viruses are safer our results indicate that they may not
provide the necessary IgA antibody response to combat respiratory infections. In general,
annual vaccination against equine influenza virus infection, tetanus, rabies and
encephalomyelitis viruses are warranted.
herpesvirus infections (118).

Most older horses will likely have latent

Reactivation of these latent infections could lead to

myeloencephalopathy or serve as a source of infection for susceptible horses (119, 120).
As there is no evidence supporting any benefit of vaccination in preventing such
occurrences in the older horses, and a possible risk of vaccination-induced reactivation,
such practices should be avoided (121). Likewise, there is little support for the use of
immunostimulatory or other supplements in the aged horse to boost immune
responsiveness. Indeed the potential risk for adverse reactions with such treatments
argues against their use until clear benefits have been shown in properly controlled
studies. More work, in general, is needed to better understand the immunological needs
of this population.
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